Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of renal and hepatic impairment on
TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with
renal or hepatic impairment.